Evidence map›Paper›PMID 41671402›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Versatile CRISPR-Cas Tools for Gene Regulation in Zebrafish via an Enhanced Q Binary System.

Miaoyuan Shi, Weiqi Ge, Changheng Li, Bin Liu, Xiaoyi Deng, Chengjie Liu, Meijun Zheng, Pu Zhang, Lei Li, Ying Guo and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Miaoyuan ShiDepartment of Nuclear Medicine, Medical Research Institute, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
Weiqi GeDepartment of Nuclear Medicine, Medical Research Institute, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
Changheng LiDepartment of Nuclear Medicine, Medical Research Institute, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
Bin LiuDepartment of Nuclear Medicine, Medical Research Institute, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
Xiaoyi DengDepartment of Nuclear Medicine, Medical Research Institute, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
Chengjie LiuDepartment of Nuclear Medicine, Medical Research Institute, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
Meijun ZhengDepartment of Nuclear Medicine, Medical Research Institute, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
Pu ZhangDepartment of Nuclear Medicine, Medical Research Institute, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
Lei LiDepartment of Nuclear Medicine, Medical Research Institute, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
Ying GuoDepartment of Nuclear Medicine, Medical Research Institute, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
Yunqi HanState Key Laboratory of Biocatalysis and Enzyme Engineeringhubei Hongshan Laboratory, School of Life Sciences, Hubei University, Wuhan, China.
Yu YangState Key Laboratory of Biocatalysis and Enzyme Engineeringhubei Hongshan Laboratory, School of Life Sciences, Hubei University, Wuhan, China.
Yanxun V YuDepartment of Neurology, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.ORCID https://orcid.org/0000-0001-6617-0166
Youngnam N JinDepartment of Nuclear Medicine, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.ORCID https://orcid.org/0009-0007-2632-3237

Funding

Fundamental Research Funds for the Central Universities 2042022dx0003National Natural Science Foundation of China 32070832National Natural Science Foundation of China 32150610476
6 · The paper itself

Abstract

CRISPR-Cas systems revolutionize gene regulation across diverse organisms, including zebrafish. However, most zebrafish studies still rely on transient delivery of CRISPR components, with limited use of transgenic models, primarily restricted to Cas9-mediated knockouts. This limitation arises from challenges in achieving sustained, tissue-specific, and efficient expression of transgenic CRISPR effectors. To address these challenges, we introduce CRISPR-Q, a transgenic system that combines the QFvpr/QUAS binary expression platform with CRISPR-Cas technologies. CRISPR-Q overcomes the drawbacks of transient mRNA or protein delivery and circumvents the toxicity and transgene silencing issues associated with other binary systems, such as Gal4/UAS. The system enables robust and spatiotemporal expression of CasRx or dCas9vpr, allowing precise transcript knockdown (CRISPR-Q

Indexed as

CRISPR-Cas SystemsGene EditingGene Expression RegulationZebrafishAnimalsAnimals, Genetically ModifiedDNA-Binding ProteinsGene Knockdown TechniquesZebrafish ProteinsDNA-Binding ProteinsTardbp protein, zebrafishZebrafish Proteinsamyotrophic lateral sclerosisCas13CRISPRaCRISPR‐CasQF/QUAStransgenicszebrafish

Identifiers

PMID41671402
PMCPMC13104143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.